Insider buying last 90 days
No open-market insider purchases were filed for BLTE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BLTE insider filing, plotted on the chart in Gekko.Open BLTE in Gekko
Gekko Brief
AI summaryBelite Bio moves this week on continued momentum around tinlarebant, with the company announcing oral presentations at two upcoming medical conferences where new data will be shared. This follows the FDA's earlier acceptance of the NDA for tinlarebant in Stargardt disease with priority review, a regulatory backdrop that continues to shape sentiment around the name.
BLTE closes at $165.93, down 0.8% on the day, sitting above both its 50-day average of $165.04 and its 200-day average of $160.57, with the shorter average above the longer one, a setup consistent with an established uptrend. The GekkoIndex reads 59, placing the stock in the Neutral zone. Shares trade 5.5% below Gekko Fair Value of $175.59, and the one-year return stands at 137%, with the 52-week range spanning $68.35 to $200.00.
The next earnings date falls on 9 November 2026, 41 days out and beyond a typical 20-trading-day holding window; the last report on 10 August showed a GAAP net loss of $28.4 million against $16.3 million a year earlier, with an 8.9% reaction following that print. No insider, Congress, or unusual options activity appears in their respective windows, though one billionaire holder is recorded. Seasonally, the next 20 trading days have averaged an 18.1% gain over 4 years, with gains in 3 of them. All 7 covering analysts rate the stock a buy, with a consensus target of $228.89.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Belite Bio price vs fair value
Close $165.93200-day averageGekko Fair Value $175.59
Belite Bio quick facts
- Market cap
- $6.65B
- P/E ratio
- —
- Forward P/E
- 416.7
- EPS, TTM
- −$2.74
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- -1.24
- Volume
- 114,228 avg 198,149
- 1-year return
- +137.0%
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±10.1%
- 50-day average
- $165.04
- 200-day average
- $160.57
- Next earnings
- Nov 9
- Shares outstanding
- 40.27M
Belite Bio swing-trade checklist
Belite Bio scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $165.93 is above the 50-day ($165.04) and 200-day ($160.57) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
59, Neutral
Reading 59 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
5.5% below
Price is 5.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 41 days
Next report Nov 9, 2026, 41 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+18.1% on average
From this point in the calendar, the next 20 trading days averaged +18.1% over 4 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Belite Bio stock chart and price history
Belite Bio closed at $165.93 on Sep 28, 2026, +137.0% over the past year, inside a 52-week range of $68.35 to $200.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +5.7%
- 3 months
- +7.3%
- 6 months
- +9.1%
- 1 year
- +137.0%
The full BLTE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BLTE in Gekko
Follow Belite Bio through every session
Put BLTE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BLTE in GekkoFree for 7 days. No credit card required.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical company that works on developing treatments still in the testing stages, rather than products already on the market. Much of its research centers on eye disorders, particularly atrophic age-related macular degeneration and a form of Stargardt disease that runs in families. Its best-known program is LBS-008, an oral drug taken once a day that is now in Phase 3 trials and is meant to control how vitamin A moves to the eye, limiting the buildup of certain vitamin A byproducts that can damage eye tissue.
The company also has a second program, LBS-009, which is being studied in earlier, preclinical stages. This candidate works by blocking retinol binding protein 4 and is intended for liver-related conditions such as fatty liver disease, steatohepatitis, and type 2 diabetes. Belite Bio functions as part of Lin Bioscience International Ltd.
Belite Bio was started in 2016 and has its main offices in San Diego, California. Its stock trades under the ticker BLTE.
- Sector
- Health technology
- Website
- belitebio.com
Belite Bio GekkoIndex: the smart money zone
Belite Bio’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59, in the Neutral zone, up 2.8 points over five sessions.
59Neutral
Up 2.8 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 24 | +2.6% | +3.6% | ||
| Accumulation | 163 | +1.2% | +5.2% | ||
| Neutral (current zone) | 345 | +1.4% | +5.6% | ||
| Distribution | 87 | +1.1% | +8.8% | ||
| Selling | 6 | Too few readings yet | |||
Average BLTE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BLTE price, zone by zone.Track BLTE in Gekko
Is Belite Bio stock overvalued? Gekko Fair Value
Belite Bio trades 5.5% below Gekko Fair Value of $175.59, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Belite Bio shares are worth, recalculated every trading day.
$175.59
Gekko Fair Value, Sep 26, 2026
5.5% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BLTE in Gekko
Belite Bio insider and Congress trading
No open-market insider purchases were filed for Belite Bio, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BLTE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BLTE, plotted on the chart in Gekko.Open BLTE in Gekko
Hedge funds and billionaires quarter ended Mar 31
1of the funds Gekko tracks holds BLTE.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Belite Bio earnings: next date and track record
Belite Bio reports on Nov 9, 2026 (41 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 9, 2026
41 days away
- EPS estimate
- −$0.79
2 of 8reports beat the EPS estimate
±5.2%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 10, 2026 AI summary
- What they said
- Belite Bio reported Q2 2026 GAAP net loss of $28.4M vs $16.3M prior year, with R&D expenses rising to $18.2M and SG&A to $16.7M due to milestone royalties and team expansion. FDA accepted the NDA for tinlarebant (Stargardt disease) with priority review and PDUFA date of February 12, 2027. Phase 3 Dragon study showed tinlarebant reduced QAF values ~2% vs ~20% increase in placebo at month 25. Cash position stands at $780M.
- Guidance
- Management expects $780M cash runway to fund commercialization of tinlarebant post-approval and advance pipeline. No specific revenue targets provided; PDUFA date set for February 12, 2027. Pediatric label expansion below age 12 is being planned.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.70 est −$0.73 | — | +8.9% |
| May 20, 2026 | −$0.68 est −$0.64 | — est $16.67M | +3.3% |
| Mar 2, 2026 | −$0.70 est −$0.54 | — est $16.67M | −11.8% |
| Nov 10, 2025 | −$0.65 est −$0.49 | — | −6.6% |
| Aug 11, 2025 | −$0.50 est −$0.47 | — | +4.1% |
| May 13, 2025 | −$0.45 est −$0.36 | — | −0.6% |
| Nov 12, 2024 | −$0.28 est −$0.29 | — | +4.6% |
| Aug 9, 2024 | −$0.31 est −$0.26 | — | −1.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Belite Bio stock forecast and analyst price targets
Analysts’ average 12-month price target for Belite Bio is $228.89, +37.9% from the last close, from 7 firms rating the stock in the last 90 days.
$228.89consensus 12-month target, +37.9% from the last close
Now $165.93Avg $228.89
Low $200High $303
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | H.C. Wainwright | $245 | +47.7% |
| Sep 9 | Mizuho Securities | $234 | +41.0% |
| Sep 8 | H.C. Wainwright | $245 | +47.7% |
| Sep 4 | Canaccord Genuity | $303 | +82.6% |
| Sep 4 | Mizuho Securities | $220 | +32.6% |
+5.6%average 20-day move after past Neutral readings
+18.1%average move over the next 20 trading days in the last 4 years
±3.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Belite Bio seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Belite Bio averaged +18.1% across the last 4 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.1% | 2 of 4 |
| Next 10 trading days | +5.4% | 3 of 4 |
| Next 15 trading days | +7.1% | 3 of 4 |
| Next 20 trading days | +18.1% | 3 of 4 |
| Next 30 trading days | +34.8% | 3 of 4 |
For scale, BLTE’s typical 20-trading-day move in either direction is about 10.1%.
Belite Bio market cap and key statistics
Belite Bio’s market cap is $6.65B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $6.65B
- Forward P/E
- 416.7
- EPS, TTM
- −$2.74
- Gekko Fair Value
- $175.59
Trading
- Volume
- 114,228
- Avg volume, 20 days
- 198,149
- 52-week high
- $200.00
- 52-week low
- $68.35
- Shares outstanding
- 40.27M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -22.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -1.24
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±10.1%
Belite Bio stock news this week
1 headline about Belite Bio from the past week, newest first, each linking to the publisher.
- Belite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesGlobeNewsWire, Sep 28
Belite Bio stock FAQ
What is Belite Bio’s market cap?
Belite Bio’s market cap is $6.65B at the Sep 28, 2026 close of $165.93, with 40.27M shares outstanding.
What is the Belite Bio stock forecast?
The consensus analyst 12-month price target for Belite Bio is $228.89, +37.9% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Belite Bio stock overvalued or undervalued?
On Gekko’s estimate Belite Bio is undervalued: the Sep 28, 2026 close of $165.93 is 5.5% below Gekko Fair Value of $175.59. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Belite Bio report earnings next?
Belite Bio is expected to report on Nov 9, 2026 (41 days away). Analysts expect earnings of −$0.79 per share. Belite Bio beat the earnings estimate in 2 of its last 8 reports, moving 5.2% on average across the report.
What is Belite Bio’s 52-week high and low?
Belite Bio’s 52-week high is $200.00 and its 52-week low is $68.35; it closed at $165.93 on Sep 28, 2026, +137.0% over the past year.
Is Belite Bio stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Belite Bio the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.